Dear Dagmar, I know the news is still fresh. There are so many things I want to tell you, but I’ll keep this letter focused. That’s mainly because I know being contacted by your future self can be startling enough, but added to that, being told you have ALS…
I feel a sense of accomplishment as this year ends. We made it. My husband, Todd, has hung on, with much effort to keep his lungs clear and filled with air, and we’ve kept persevering even as his ALS keeps progressing. Todd hasn’t had his breathing tested since December…
Throughout 2025, ALS News Today delivered readers timely reporting on research breakthroughs, patient advocacy, potential treatments, and diagnostic advances for amyotrophic lateral sclerosis (ALS). Below are the top 10 most-read news stories for a recap of the year, each accompanied by a summary. As we enter 2026, we…
Actor Eric Dane, who is living with amyotrophic lateral sclerosis (ALS), has joined the board of directors of Target ALS, a U.S.-based advocacy and research organization. His goal? Furthering his personal commitment to advancing research into the progressive disease and supporting the nonprofit’s effort to find effective treatments…
An experimental, noninvasive device for slowing the progression of functional symptoms in people with amyotrophic lateral sclerosis (ALS) has been awarded breakthrough device designation by the U.S. Food and Drug Administration (FDA). Called MyoRegulator, the neuromodulation device from Pathmaker Neurosystems aims to reduce excessive nerve cell activation,…
Every year, I make and sell Christmas wreaths. Much of my day is filled with caring for my husband, Todd, who has ALS, along with household tasks such as laundry, meals, dishes, and snow removal. But I often have a couple of hours each day — after I set…
NUZ-001, an investigational oral therapy being developed by Neurizon Therapeutics for the treatment of amyotrophic lateral sclerosis (ALS), is officially the ninth compound to be included in the HEALEY ALS platform trial. The announcement follows clearance by the U.S. Food and Drug Administration (FDA) of an amended trial protocol,…
December is traditionally a cherished time for holiday festivities and reflecting on the year that has passed. This month, I am sending bucketfuls of gratitude to my friends and family for their love and support, and I thank my readers for choosing to spend their time with me. Yet, as…
The U.S. Food and Drug Administration (FDA) has cleared the start of a pivotal Phase 3 clinical trial testing the oral therapy pridopidine in people with amyotrophic lateral sclerosis (ALS). Dubbed PREVAiLS, the trial will assess pridopidine’s efficacy and safety in up to 500 people with early, rapidly progressive ALS,…
Qalsody (tofersen) is one step closer to being covered by public Canadian healthcare systems when used to treat adults with amyotrophic lateral sclerosis (ALS) who carry mutations in the SOD1 gene (SOD1-ALS). Developed by Biogen, the therapy was conditionally approved by Health Canada in March, allowing…
